Azathioprine in the management of autoimmune uveitis

Ocular Immunology and Inflammation

Volumn 16, Issue 4, 2008, Pages 161-165

  Pacheco, Patricio A ^a   Taylor, Simon R J ^b   Cuchacovich, Miguel T ^c   Diaz, Gonzalo V ^d  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HOSPITAL CLÍNICO UNIVERSIDAD DE CHILE   (Chile)

^d UNIVERSITY OF CHILE   (Chile)

Author keywords

Autoimmune; Azathioprine; Inflammation; Steroid resistant; Uveitis

Indexed keywords

ACICLOVIR; ANTIBIOTIC AGENT; AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; PREDNISOLONE;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOIMMUNE DISEASE; BEHCET DISEASE; CATARACT; CAUCASIAN; CENTRAL SEROUS RETINOPATHY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG TOLERABILITY; EPIRETINAL MEMBRANE; FEMALE; GASTROINTESTINAL SYMPTOM; HERPES ZOSTER; HUMAN; INTERMEDIATE UVEITIS; INTRAOCULAR HYPERTENSION; IRIDOCYCLITIS; LEUKOPENIA; MAINTENANCE DRUG DOSE; MALE; MIGRAINE; OPTIC NEURITIS; PATIENT CARE; PATIENT COMPLIANCE; RETINA ANEURYSM; RETINA DETACHMENT; RETINA DISEASE; RETINA MACULA CYSTOID EDEMA; SIDE EFFECT; TREATMENT OUTCOME; TREATMENT RESPONSE; URINARY TRACT INFECTION; UVEITIS; VOGT KOYANAGI SYNDROME;

ADOLESCENT; ADULT; AGED; AUTOIMMUNE DISEASES; AZATHIOPRINE; DRUG RESISTANCE; FEMALE; GLUCOCORTICOIDS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; PREDNISOLONE; UVEITIS; YOUNG ADULT;

EID: 50049111675     PISSN: 09273948     EISSN: 17445078     Source Type: Journal    
DOI: 10.1080/09273940802204519     Document Type: Article

References (14)

1. Tamesis RR, et al. Systemic drug toxicity trends in immunosuppressive therapy of immune and inflammatory ocular disease. Ophthalmology. 1996;103:768-775.
2. Hemady R, Tauber J, Foster CS. Immunosuppressive drugs in immune and inflammatory ocular disease. Surv Ophthalmol. 1991;35:369-385.
3. Nussenblatt RB, Palestine AG, Chan CC. Cyclosporin A therapy in the treatment of intraocular inflammatory disease resistant to systemic corticosteroids and cytotoxic agents. Am J Ophthalmol. 1983; 96: 275-282.
4. Wang CL, Wang F, Bosco JJ. Ovarian failure in oral cyclophosphamide treatment for systemic lupus erythematosus. Lupus. 1995;4:11-14.
5. Vitale AT, Rodriguez A, Foster CS. Low-dose cyclosporin A therapy in treating chronic, noninfectious uveitis. Ophthalmology. 1996;103:365-373; discussion 373-374.
6. Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol. 2005;140:509-516.
7. Fuentes D, et al. High-dose azathioprine in children with inflammatory bowel disease. Aliment Pharmacol Ther. 2003;17:913-921.
8. Nussenblatt RB, et al. Standardization of vitreal inflammatory activity in intermediate and posterior uveitis. Ophthalmology. 1985;92:467-471.
9. Corley CC, Jr, Lessner HE, Larsen WE. Azathioprine therapy of "autoimmune" diseases. Am J Med. 1966;41:404-412.
10. Greenwood AJ, Stanford MR, Graham EM. The role of azathioprine in the management of retinal vasculitis. Eye. 1998;12:783-788.
11. Hamuryudan V, et al. Azathioprine in Behcet's syndrome: effects on long-term prognosis. Arthritis Rheum. 1997;40:769-774.
12. Mee J, et al. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J Neuroophthalmol. 2003;23:251-255.
13. Thorne JE, et al. Mycophenolate mofetil therapy for inflammatory eye disease. Ophthalmology. 2005;112:1472-1477.
14. Yazici H, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322:281-285.